Immunotherapy with Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients with Cancer

David Bomze*, Daniel Azoulay, Tomer Meirson

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)1114-1115
Number of pages2
JournalJAMA Oncology
Volume6
Issue number7
DOIs
StatePublished - Jul 2020
Externally publishedYes

Funding

FundersFunder number
Ensign Endowment for Gynecologic Cancer Research
National Institutes of Health
American Cancer Society
National Cancer InstituteNCI CA217685
Breast Cancer Research Foundation
AstraZeneca
MerckR01CA169121-01A1
Patient-Centered Outcomes Research Institute
Meso Scale Diagnostics

    Cite this